MI

Milestone Pharmaceuticals IncNASDAQ MIST Stock Report

Last reporting period 31 Dec, 2023

Updated 22 Nov, 2024

Last price

Market cap $B

0.082

Micro

Exchange

XNAS - Nasdaq

MIST Stock Analysis

MI

Uncovered

Milestone Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-52/100

Low score

Market cap $B

0.082

Dividend yield

Shares outstanding

34.286 B

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 29 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent and short-acting calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is developing etripamil for the treatment of arrhythmias with an indication to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

View Section: Eyestock Rating